Market Closed -
Other stock markets
|
|
5-day change | 1st Jan Change | |
116.62 USD | +0.95% | +3.25% | +2.98% |
Nov. 29 | Transcript : DexCom, Inc. Presents at Piper Sandler 35th Annual Healthcare Conference, Nov-29-2023 08:30 AM | CI |
Nov. 17 | Wall Street: still positive bias ahead of the '3 Witches | CF |
Financials (USD)
Sales 2023 * | 3,592 M | Sales 2024 * | 4,309 M | Capitalization | 45.06 B |
---|---|---|---|---|---|
Net income 2023 * | 443 M | Net income 2024 * | 665 M | EV / Sales 2023 * | 13,0x |
Net Debt 2023 * | 1,790 M | Net Debt 2024 * | 1,107 M | EV / Sales 2024 * | 10,7x |
P/E ratio 2023 * | 108x | P/E ratio 2024 * | 71,5x | Employees | 7,550 |
Yield 2023 * | - | Yield 2024 * | - | Free-Float | 94.84% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
More news
1 day | +0.95% | ||
1 week | +3.25% | ||
Current month | +0.95% | ||
1 month | +24.50% | ||
3 months | +14.45% | ||
6 months | -4.85% | ||
Current year | +2.98% |
1 week
111.29
117.50

1 month
91.49
117.50

Current year
74.75
139.55

1 year
74.75
139.55

3 years
66.89
164.86

5 years
26.26
164.86

10 years
7.02
164.86

Managers | Title | Age | Since |
---|---|---|---|
Kevin Sayer
CEO | Chief Executive Officer | 65 | 2007 |
Jereme Sylvain
DFI | Director of Finance/CFO | 43 | 2018 |
Chief Tech/Sci/R&D Officer | 46 | 2022 |
Members of the board | Title | Age | Since |
---|---|---|---|
Mark Foletta
BRD | Director/Board Member | 62 | 2014 |
Eric Topol
BRD | Director/Board Member | 68 | 2009 |
Kevin Sayer
CEO | Chief Executive Officer | 65 | 2007 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
9.01% | 4 M€ | -.--% | ||
6.15% | 5 M€ | -18.69% | ||
5.12% | 3 M€ | +7.59% | ||
5.11% | 238 M€ | +12.21% |
Date | Price | Change | Volume |
---|---|---|---|
23-12-01 | 116.62 | +0.95% | 3,075,029 |
23-11-30 | 115.52 | -0.57% | 4,537,499 |
23-11-29 | 116.18 | +3.55% | 4,734,844 |
23-11-28 | 112.20 | -1.56% | 4,492,399 |
23-11-27 | 113.98 | +0.91% | 3,687,258 |
Delayed Quote Nasdaq, December 01, 2023 at 04:00 pm EST
More quotes
DexCom, Inc. specializes in the design, manufacture and marketing of continuous glucose monitoring (CGM) systems for people with diabetes and healthcare providers. The company provides an implantable device for continuous measurement of blood glucose levels and an external transmitter to which the sensor transmits glucose levels at specified intervals.
The United States accounts for 73.6% of net sales.
Calendar
2024-02-07
- Q4 2023 Earnings Release (Projected)
Trading Rating :
Investor Rating :
ESG Refinitiv :
B-
Sell
Buy

Mean consensus
BUY
Number of Analysts
23
Last Close Price
116.62USD
Average target price
125.37USD
Spread / Average Target
+7.51%
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+2.98% | 45 059 M $ | |
-4.47% | 182 B $ | |
+2.92% | 106 B $ | |
-6.31% | 68 780 M $ | |
+23.16% | 40 616 M $ | |
+29.59% | 39 198 M $ | |
+49.48% | 26 029 M $ | |
-7.47% | 24 653 M $ | |
-23.59% | 23 949 M $ | |
+25.47% | 23 774 M $ |